Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Impavido

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
ABSTRACT An open-label pharmacokinetics (PK) clinical trial was conducted to comparatively assess the PK and explore the… Expand
2016
2016
Miltefosine was developed to treat skin cancer; further studies showed that the drug also has activity against Leishmania… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 2
2015
2015
We describe the safety and efficacy of treating visceral leishmaniasis (VL) in patients with human immunodeficiency virus-VL… Expand
  • figure 1
  • table 2
  • table 1
  • table 3
  • table 4
2013
2013
The thesis focused on the study of raptors movements by means of satellite telemetry and is based mainly on the Eleonora's falcon… Expand
  • figure 3
  • figure 4
  • figure 5
  • table 2
  • figure 3
2012
2012
Autoři předkladaji kazuistiku pacienta s febrilni pancytopenii, hepatosplenomegalii a vahovým ubytkem, u ktereho byla složit… Expand
2006
2006
Perifosine is a novel alkylphospholipid. Perifosine has displayed significant antiproliferative activity in vitro and in vivo in… Expand
  • table 1
  • figure 1
2004
2004
Hexadecylphosphocholine (HDPC, Miltefosine, Impavido) was synthesized at the Max-Planck-Institut für Biophysikalische Chemie in G… Expand
Highly Cited
2003
Highly Cited
2003
Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5